|
gptkbp:instance_of
|
gptkb:weapon
gptkb:chemical_compound
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:lambert-eaton_syndrome
gptkb:methotrexate
gptkb:actinomycin_D
|
|
gptkbp:activities
|
gptkb:weapon
alkylation of DNA
|
|
gptkbp:affects
|
rapidly dividing cells
|
|
gptkbp:appointed_by
|
oral tablet
intravenous injection
|
|
gptkbp:associated_with
|
cardiotoxicity
pulmonary toxicity
hemorrhagic cystitis
|
|
gptkbp:brand
|
gptkb:Cytoxan
|
|
gptkbp:can_be_used_with
|
gptkb:vincristine
gptkb:methotrexate
gptkb:rituximab
gptkb:trastuzumab
gptkb:prednisone
gptkb:taxanes
anthracyclines
cyclophosphamide and carboplatin
cyclophosphamide and doxorubicin
cyclophosphamide and etoposide
platinum-based drugs
|
|
gptkbp:contraindication
|
pregnancy
active infections
severe bone marrow suppression
|
|
gptkbp:developed_by
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:discovered_by
|
1950s
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
cyclophosphamide
|
|
gptkbp:ingredients
|
C7 H15 Cl2 N2 O2 P
|
|
gptkbp:interacts_with
|
gptkb:warfarin
gptkb:dexamethasone
mesna
|
|
gptkbp:investment
|
secondary malignancies
|
|
gptkbp:is_atype_of
|
L01 A A01
|
|
gptkbp:is_available_on
|
generic drug
|
|
gptkbp:is_used_for
|
gptkb:healthcare_organization
autoimmune diseases
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:related_to
|
gptkb:ifosfamide
gptkb:busulfan
gptkb:chlorambucil
|
|
gptkbp:side_effect
|
nausea
vomiting
hair loss
bone marrow suppression
bladder toxicity
|
|
gptkbp:type_of
|
6055-19-2
|
|
gptkbp:used_in
|
immunosuppressive therapy
chemotherapy regimens
|